Azienda Ospedaliero Universitaria Pisana

The research program at Azienda Ospedaliero Universitaria Pisana includes studies in immune system diseases, systemic lupus erythematosus, lupus nephritis, and Sjögren’s syndrome. These trials are focused on testing new treatment options and understanding how to better control disease activity and systemic symptoms.

• Active, refractory systemic lupus erythematosus and lupus nephritis
• Sjögren’s syndrome with moderate-to-severe systemic disease activity
• General immune system diseases and immune-related processes

Much of this work aims to improve long-term disease control, reduce flare-ups, and evaluate whether emerging therapies can offer safer and more effective care.

Several trials at this site address chronic kidney disease, high proteinuria, obesity, and related metabolic disorders. The main goal is to slow kidney decline, reduce protein loss, and explore therapies that may improve overall metabolic health.

• Chronic kidney disease with or without type 2 diabetes
• Chronic kidney disease and high proteinuria
• Obesity and metabolic regulation

These studies reflect a strong interest in protecting kidney function while also addressing the broader metabolic factors that can worsen long-term outcomes.

The site is also active in neurological research, with trials in Alzheimer’s disease, migraine, chronic inflammatory demyelinating polyneuropathy, and facioscapulohumeral muscular dystrophy. This area focuses on both symptom control and the development of treatments that may preserve function over time.

• Alzheimer’s disease
• Chronic or episodic migraine
• CIDP and FSHD

Research here aims to improve safety, reduce neurological burden, and evaluate whether new therapies can support mobility, cognition, and quality of life.

Clinical trials in digestive system diseases include work on ulcerative colitis and gastroesophageal adenocarcinoma. These studies are designed to test better treatments for inflammation and to improve outcomes in difficult-to-treat gastrointestinal cancers.

• Moderate to severe ulcerative colitis
• Locally advanced resectable gastroesophageal adenocarcinoma
• Digestive system disease research more broadly

The focus is on improving disease control, reducing relapse, and evaluating whether newer therapies can deliver better results than current standard care.

This oncology portfolio spans solid tumors and blood cancers, including colorectal cancer, liver cancer, lung cancer, breast cancer, pancreatic cancer, multiple myeloma, and acute myeloid leukemia. The trials are centered on testing new treatments, improving survival, and refining cancer control strategies.

• Advanced colorectal cancer with KRAS G12C mutation
• Advanced hepatocellular carcinoma and metastatic pancreatic ductal adenocarcinoma
• Multiple myeloma and newly diagnosed AML with NPM1 mutation

At PO Santa Chiara-UO Reumatologia, this area of research also includes studies of treatment combinations and perioperative approaches aimed at better tumor response and longer disease control.

Additional trials cover cardiovascular disease, eye disease, and selected other conditions such as atherosclerotic cardiovascular disease, uveal melanoma, and Langerhans cell histiocytosis. These studies are designed to evaluate new therapies, improve organ-specific outcomes, and address conditions with limited treatment options.

• Atherosclerotic cardiovascular disease and elevated Lp(a)
• Uveal melanoma and vision-threatening eye cancer
• Langerhans cell histiocytosis and related immune-mediated disease

This mix of research highlights a broad clinical focus, combining preventive care, cancer treatment, and rare disease management within a single hospital-based setting.